

**REMARKS**

Claims 1-10, 18-21, 27-29, 34, 37 and 38 are pending in this application. By this Amendment, claims 1, 18, 19, 27 and 29 are amended. The amendments introduce no new matter because they are supported by at least paragraphs [0132] and [0133] of the specification, as originally filed. Claims 11-17, 22-26, 30-33, 35 and 36 are canceled without prejudice to, or disclaimer of, the subject matter recited in those claims. A Request for Continued Examination is attached. Reconsideration of the application based on the above amendments and the following remarks is respectfully requested.

Applicants appreciate the courtesies extended to Applicants' representatives by Examiner Garrett in the March 8, 2006 personal interview. Applicants' separate record of a summary of the substance of the personal interview is contained in the following remarks.

The Office Action, in paragraph 1, reiterates that claims 11-17, 22-26, 30-33, 35 and 36 are withdrawn as non-elected. Claims 11-17, 22-26, 30-33, 35 and 36 are canceled.

The Office Action, in paragraph 6, rejects claims 1-6, 8-10, 18-21, 27-29, 34, 37 and 38 under 35 U.S.C. §102(e) as being anticipated by U.S. Patent No. 6,372,154 to Li. This rejection is respectfully traversed.

The Office Action alleges that Li discloses the combinations of features recited in the pending claims. Applicants previously argued that Li fails to disclose a range of solubility parameters of the additive and the additional materials that correspond to the metal deactivator as recited in independent claims 1, 18, 19, 27 and 29. The Office Action asserts, in paragraph 8, that Applicants have not shown that the materials of Li do not possess the added property limitations. It is not a requirement for Applicants to show such limitations. Rather, in making a rejection of pending claims under 35 U.S.C. §102, all of the features recited in the pending claims must be shown explicitly or inherently disclosed in the single prior art reference. This standard is not met here. The Office Action does not attempt to

show, in any way, that the specific solubility parameters recited in the pending claims are met by Li. As such, the Office Action fails to make a *prima facie* case for anticipation of the positively recited claim features. Burden, therefore, is not shifted to the Applicants to show that such a feature is not present in the applied prior art references.

Li also neither discloses, nor can it reasonably be considered to have suggested the metal deactivator in a range of 0.1 to 10 percent by weight relative to the functional element as is positively recited in each of the independent claims.

For at least these reasons, Li neither teaches, nor can it reasonably be considered to have suggested, the combinations of all of the features recited in independent claims 1, 18, 19, 27 and 29. Further, claims 2-6, 8-10, 19-21, 28, 34, 37 and 38 are also neither taught, nor would they have been suggested, by Li for at least the respective dependence of these claims directly or indirectly on allowable independent claims, as well as for the separately patentable subject matter that each of these claims recites.

Accordingly, reconsideration and withdrawal of the rejection of claims 1-6, 8-10, 18-21, 27-29, 34, 37 and 38 under 35 U.S.C. §102(e) as being anticipated by Li are respectfully requested.

The Office Action, in paragraph 7, rejects claims 1-10, 18-21, 27-29, 34, 37 and 38 under 35 U.S.C. §102(e) as being anticipated by U.S. Patent Application Publication No. US 2004/0062947 to Lamansky et al. (hereinafter "Lamansky"). This rejection is respectfully traversed.


The Office Action asserts that Lamansky is considered to teach the combinations of all of the features recited in the pending claims. Lamansky neither teaches, nor can it reasonably be considered to have suggested, a feature of a metal deactivator in a content of 0.1 to 10 percent by weight relative to the functional element as is positively recited in independent claims 1, 18, 19, 27 and 29. As such, Lamansky cannot reasonably be considered to teach, or

to have suggested, the combinations of all of the features recited in these claims. Further, claims 2-10, 19-21, 28, 34, 37 and 38 are also neither taught, nor would they have been suggested, by Lamansky for at least the respective dependence of these claims directly or indirectly on allowable independent claims, as well as for the separately patentable subject matter that each of these claims recites.

In view of the foregoing, Applicants respectfully submit that this application is in condition for allowance. Favorable reconsideration and prompt allowance of claims 1-10, 18-21, 27-29, 34, 37 and 38 are earnestly solicited.

Should the Examiner believe that anything further would be desirable in order to place this application in even better condition for allowance, the Examiner is invited to contact Applicants' undersigned representative at the telephone number set forth below.

Respectfully submitted,



James A. Oliff  
Registration No. 27,075

Daniel A. Tanner, III  
Registration No. 54,734

JAO:DAT/gck

Attachment:  
Request for Continued Examination

Date: March 28, 2006

**OLIFF & BERRIDGE, PLC**  
**P.O. Box 19928**  
**Alexandria, Virginia 22320**  
**Telephone: (703) 836-6400**

<p><b>DEPOSIT ACCOUNT USE AUTHORIZATION</b> Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461</p>
---